Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
EC to Investigate Arsenal, DSM Deal
August 11, 2008
| A version of this story appeared in
Volume 86, Issue 32
The European Commission has launched an "in-depth" investigation into competitive implications of Arsenal Capital Partners' planned purchase of DSM's specialty products business (C&EN, March 10, page 14). DSM and Arsenal's Velsicol Chemical unit are two of the world's largest manufacturers of benzoic acid and sodium benzoate, used in a variety of food, pharmaceutical, and animal feed products. According to EC Competition Commissioner Neelie Kroes, the chemicals are "essential to consumers and the competitiveness of European industry, which would be harmed by a reduction of competition." The EC will make a determination by Dec. 11.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter